{"success":true,"data":{"pressRelease":{"id":"133919","rtpr_id":"nPn44zLBLa","ticker":"HALO","exchange":"NASDAQ","all_tickers":["HALO"],"title":"Halozyme to Participate at Upcoming Investor Conferences","author":"PR Newswire","published_at":"2026-09-02T12:30:03.704Z","article_body":"Halozyme to Participate at Upcoming Investor Conferences\n\nPR Newswire\n\nSAN DIEGO, Sept. 2, 2026\n\nSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq:\nHALO) (\"Halozyme\") today announced that Dr. Helen Torley, President and Chief\nExecutive Officer, and Darren Snellgrove, Chief Financial Officer, are\nscheduled to participate and host investor meetings at the following investor\nconferences.\n\nDetails on the Company's participation are as follows:\n\nEvent: Wells Fargo 21(st) Annual Healthcare Conference\nFormat: Fireside Chat and 1x1 Meetings\nPresentation Date: Wednesday, September 9, 2026\nPresentation Time: 12:45pm PT / 3:45pm ET\n\nEvent: Morgan Stanley 24(th) Annual Global Healthcare Conference\nFormat: Fireside Chat and 1x1 Meetings\nDate: Tuesday, September 15, 2026\nPresentation Time: 4:45am PT / 7:45am ET\n\nEvent: H.C. Wainwright 28(th) Annual Global Investment Conference\nFormat: Fireside Chat and 1x1 Meetings\nDate: Wednesday, September 16, 2026\nPresentation Time: 7:00am PT / 10:00am ET\n\nA live audio webcast of the presentations will be available in the Investor\nRelations section of the Company's website. Replays of the audio webcasts will\nbe available for 90 days following the conference.\n\nAbout Halozyme\n\nHalozyme is a biopharmaceutical company advancing disruptive solutions to\nimprove patient experiences and outcomes for emerging and established\ntherapies. As the innovators of ENHANZE® drug delivery technology with the\nproprietary enzyme rHuPH20, Halozyme's commercially-validated solution\nfacilitates the subcutaneous delivery of injected drugs and fluids, reducing\ntreatment burden and improving convenience. ENHANZE® has touched more than\none million patient lives through ten commercialized products across over 100\nglobal markets and is licensed to leading pharmaceutical and biotechnology\ncompanies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly,\nBristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen\nPharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte.\n\nHalozyme expanded its drug delivery technology portfolio to develop partner\nproducts using Hypercon™ and Surf Bio's hyperconcentration technology.\nHypercon™ is an innovative microparticle technology expected to set a new\nstandard in hyperconcentration of drugs and biologics by reducing injection\nvolume for the same dosage and enabling administration in at-home and\nhealthcare-provider settings. The addition of Surf Bio's polymer-based\nhyperconcentration technology further broadens the range of biologics that can\nbe delivered subcutaneously, meaningfully expanding the scope of opportunities\nacross therapeutic modalities. Together, Hypercon™ and Surf Bio's technology\ncomplement ENHANZE® by enabling creation and delivery of highly concentrated\nbiologics. The Hypercon™ technology has been licensed to leading\nbiopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex\nPharmaceuticals, and Oruka Therapeutics.\n\nHalozyme also develops, manufactures and commercializes drug-device\ncombination products using advanced auto-injector technologies designed to\nimprove convenience, reliability and tolerability, enhancing patient comfort\nand adherence. The Company has two proprietary commercial products, Hylenex®\nand XYOSTED®, partnered commercial products and ongoing development programs\nwith Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of\nViatris Inc.\n\nHalozyme is headquartered in San Diego, CA, with offices in Ewing, NJ;\nMinnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations\nfacility.\n\nContacts:\n\nTram Bui\nVP, Investor Relations and Corporate Communications\n609-333-7668\ntbui@halozyme.com (mailto:tbui@halozyme.com)\n\nSydney Charlton\nTeneo\n917-972-8407\nsydney.charlton@teneo.com (mailto:sydney.charlton@teneo.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302867162.html\n(https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302867162.html)\n\nSOURCE Halozyme Therapeutics, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS254664/Halozyme-Therapeutics-Logo.jpg?id=OA2924479\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn44zLBLa","title":"Halozyme to Participate at Upcoming Investor Conferences","author":"PR Newswire","ticker":"HALO","created":"2026-09-02T12:30:03.704Z","tickers":["HALO"],"exchange":"NASDAQ","article_body":"Halozyme to Participate at Upcoming Investor Conferences\n\nPR Newswire\n\nSAN DIEGO, Sept. 2, 2026\n\nSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq:\nHALO) (\"Halozyme\") today announced that Dr. Helen Torley, President and Chief\nExecutive Officer, and Darren Snellgrove, Chief Financial Officer, are\nscheduled to participate and host investor meetings at the following investor\nconferences.\n\nDetails on the Company's participation are as follows:\n\nEvent: Wells Fargo 21(st) Annual Healthcare Conference\nFormat: Fireside Chat and 1x1 Meetings\nPresentation Date: Wednesday, September 9, 2026\nPresentation Time: 12:45pm PT / 3:45pm ET\n\nEvent: Morgan Stanley 24(th) Annual Global Healthcare Conference\nFormat: Fireside Chat and 1x1 Meetings\nDate: Tuesday, September 15, 2026\nPresentation Time: 4:45am PT / 7:45am ET\n\nEvent: H.C. Wainwright 28(th) Annual Global Investment Conference\nFormat: Fireside Chat and 1x1 Meetings\nDate: Wednesday, September 16, 2026\nPresentation Time: 7:00am PT / 10:00am ET\n\nA live audio webcast of the presentations will be available in the Investor\nRelations section of the Company's website. Replays of the audio webcasts will\nbe available for 90 days following the conference.\n\nAbout Halozyme\n\nHalozyme is a biopharmaceutical company advancing disruptive solutions to\nimprove patient experiences and outcomes for emerging and established\ntherapies. As the innovators of ENHANZE® drug delivery technology with the\nproprietary enzyme rHuPH20, Halozyme's commercially-validated solution\nfacilitates the subcutaneous delivery of injected drugs and fluids, reducing\ntreatment burden and improving convenience. ENHANZE® has touched more than\none million patient lives through ten commercialized products across over 100\nglobal markets and is licensed to leading pharmaceutical and biotechnology\ncompanies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly,\nBristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen\nPharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte.\n\nHalozyme expanded its drug delivery technology portfolio to develop partner\nproducts using Hypercon™ and Surf Bio's hyperconcentration technology.\nHypercon™ is an innovative microparticle technology expected to set a new\nstandard in hyperconcentration of drugs and biologics by reducing injection\nvolume for the same dosage and enabling administration in at-home and\nhealthcare-provider settings. The addition of Surf Bio's polymer-based\nhyperconcentration technology further broadens the range of biologics that can\nbe delivered subcutaneously, meaningfully expanding the scope of opportunities\nacross therapeutic modalities. Together, Hypercon™ and Surf Bio's technology\ncomplement ENHANZE® by enabling creation and delivery of highly concentrated\nbiologics. The Hypercon™ technology has been licensed to leading\nbiopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex\nPharmaceuticals, and Oruka Therapeutics.\n\nHalozyme also develops, manufactures and commercializes drug-device\ncombination products using advanced auto-injector technologies designed to\nimprove convenience, reliability and tolerability, enhancing patient comfort\nand adherence. The Company has two proprietary commercial products, Hylenex®\nand XYOSTED®, partnered commercial products and ongoing development programs\nwith Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of\nViatris Inc.\n\nHalozyme is headquartered in San Diego, CA, with offices in Ewing, NJ;\nMinnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations\nfacility.\n\nContacts:\n\nTram Bui\nVP, Investor Relations and Corporate Communications\n609-333-7668\ntbui@halozyme.com (mailto:tbui@halozyme.com)\n\nSydney Charlton\nTeneo\n917-972-8407\nsydney.charlton@teneo.com (mailto:sydney.charlton@teneo.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302867162.html\n(https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302867162.html)\n\nSOURCE Halozyme Therapeutics, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS254664/Halozyme-Therapeutics-Logo.jpg?id=OA2924479\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-02T12:30:03.763959316Z","server_sent_at_ms":1788352203763},"received_at":"2026-09-02T12:30:03.850Z","source_url":"https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302867162.html"},"analysis":{"id":"122810","press_release_id":"133919","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Halozyme management will participate in three healthcare investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference on September 9, the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16.\n\nCEO Dr. Helen Torley and CFO Darren Snellgrove will host fireside chats and 1x1 meetings at each event, with live audio webcasts available on the company's Investor Relations site and replays archived for 90 days.\n\nThe release carries no new financial, clinical, or strategic disclosure -- it is a routine IR scheduling notice, with the remainder of the text drawn from standard company boilerplate on ENHANZE, Hypercon, and its auto-injector portfolio.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor-conference calendar notice with no new disclosure -- suppress from news feeds."},"keyFigures":{},"namedEntities":{"people":[{"name":"Dr. Helen Torley","role":"President and Chief Executive Officer"},{"name":"Darren Snellgrove","role":"Chief Financial Officer"},{"name":"Tram Bui","role":"VP, Investor Relations and Corporate Communications"}],"products":["ENHANZE","rHuPH20","Hypercon","Surf Bio hyperconcentration technology","Hylenex","XYOSTED"],"companies":[{"name":"Halozyme Therapeutics, Inc.","ticker":"HALO","relationship":"filer"},{"name":"Wells Fargo","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"Roche","relationship":"licensing partner"},{"name":"Takeda","relationship":"licensing partner"},{"name":"Pfizer","relationship":"licensing partner"},{"name":"Janssen","relationship":"licensing partner"},{"name":"Eli Lilly","relationship":"licensing partner"},{"name":"argenx","relationship":"licensing partner"},{"name":"GSK","relationship":"licensing partner"},{"name":"Incyte","relationship":"licensing partner"},{"name":"Teva Pharmaceuticals","relationship":"development partner"},{"name":"Viatris Inc.","relationship":"partner via McDermott Laboratories affiliate"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations calendar notice announcing management participation at three September healthcare conferences. Contains no new financial, clinical, regulatory, or strategic disclosure."},"tickerRelevance":{"others":[],"primary":"HALO"},"globalImportance":5,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"routine IR conference participation","issuerAuthored":true,"newInformation":false,"householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Halozyme management will participate in three healthcare investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference on September 9, the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16.\n\nCEO Dr. Helen Torley and CFO Darren Snellgrove will host fireside chats and 1x1 meetings at each event, with live audio webcasts available on the company's Investor Relations site and replays archived for 90 days.\n\nThe release carries no new financial, clinical, or strategic disclosure -- it is a routine IR scheduling notice, with the remainder of the text drawn from standard company boilerplate on ENHANZE, Hypercon, and its auto-injector portfolio.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Helen Torley","role":"President and Chief Executive Officer"},{"name":"Darren Snellgrove","role":"Chief Financial Officer"},{"name":"Tram Bui","role":"VP, Investor Relations and Corporate Communications"}],"products":["ENHANZE","rHuPH20","Hypercon","Surf Bio hyperconcentration technology","Hylenex","XYOSTED"],"companies":[{"name":"Halozyme Therapeutics, Inc.","ticker":"HALO","relationship":"filer"},{"name":"Wells Fargo","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"Roche","relationship":"licensing partner"},{"name":"Takeda","relationship":"licensing partner"},{"name":"Pfizer","relationship":"licensing partner"},{"name":"Janssen","relationship":"licensing partner"},{"name":"Eli Lilly","relationship":"licensing partner"},{"name":"argenx","relationship":"licensing partner"},{"name":"GSK","relationship":"licensing partner"},{"name":"Incyte","relationship":"licensing partner"},{"name":"Teva Pharmaceuticals","relationship":"development partner"},{"name":"Viatris Inc.","relationship":"partner via McDermott Laboratories affiliate"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T15:17:02.492Z","global_importance":5,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"routine IR conference participation","issuerAuthored":true,"newInformation":false,"householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":289187,"modelName":"glm-4.7"}}